Press Releases

 
Press Releases
  Date Title and Summary View
May 25, 2016
REDWOOD CITY, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa® (patiromer) for oral suspension based on results of 12...
May 22, 2016
REDWOOD CITY, Calif., May 22, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa® (patiromer) for oral suspension were presented at the 53rd Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) ...
May 18, 2016
REDWOOD CITY, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 16, 2016, the compensation committee of the company's board of directors granted 4 new employees options to purchase an aggregate of 10,400 shares of the company's common stock with a per share exercise pric...
May 5, 2016
REDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 2, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 5,700 shares of the company's common stock with a per share exercise price ...
May 4, 2016
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2016. Total revenues for the first quarter 2016 were $12.4 million, wh...
May 3, 2016
REDWOOD CITY, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior secured term loans (the "Loans"), led by funds advised by Athyrium Capital Management and joined by HealthCare Royalty Partners. The Loans are senior s...
May 2, 2016
REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10, 2016 at 3:00 p.m. PT. To access the live webcasts and subsequent archived recordings of these pr...
Apr 28, 2016
REDWOOD CITY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced data from new analyses of studies with Veltassa® (patiromer) for oral suspension were presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings in Boston. "The data presented today demo...
Apr 27, 2016
REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results on Wednesday, May 4, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at...
Apr 25, 2016
ST. GALLEN, Switzerland and REDWOOD CITY, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that VFMCRP has submitted a Marketing Authorization Application (MAA) t...
Page:
1
... NextLast
= add release to Briefcase